Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields

This article was originally published in The Pink Sheet Daily

Executive Summary

In the latest round of price cuts announced this week, Pfizer Inc. (combined with Wyeth) took the biggest hit, with 17 products seeing prices slashed.

You may also be interested in...



Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma

SHANGHAI - China's pharma market is expected to continue to grow in the next five years with a CAGR of 23.2%, which will be backed largely by the expansion of community health centers across tier 2 and tier 3 cities, according to a report issued by consultancy IMS Health

Are Chinese Price Cut Fears Overstated? Volume Likely To Drive Pharma Industry Growth, Analysts Say

SHANGHAI - As China gets closer to completing its initial $124 billion healthcare reforms next year, analysts are expecting a strong surge in volume-driven growth backed by more provincial drug reimbursement. A top priority of the Chinese reforms is to extend healthcare insurance to 90 percent (1.3 billion) of China's population by the end of 2011, a goal most expect the government to reach

China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected

SHANGHAI - China's National Development and Reform Commission has released long-awaited price cuts that will mostly affect multinational pharma companies

Related Content

Topics

UsernamePublicRestriction

Register

PS072062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel